Canadian grants & funding programs

Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Mental Health Equity for Traditionally Underserved Populations (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental health treatments and services to improve mental health outcomes for underserved populations in under-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities are strongly encouraged, including due consideration of the needs of individuals across the life span.

United States

NGO Stabilization Fund

75% funding for governance, capacity building, and operational support for NGOs.

Recognizing that many NGOs deliver essential services that support Government of the Northwest Territories (GNWT) policy objectives, the NGO Stabilization Fund was established in 2009 to help stabilize or develop the capacity of crucial NGOs who deliver critical GNWT funded programs or services to Northwest Territories (NWT) residents, such as organizations dealing with homelessness, addictions services, and shelters for women and families.

Northwest Territories

City of Niagara Falls – Community Improvement Plan: Tax Increment-Based Grant (TIBG)

A percentage of the post-improvement municipal tax increment rebated for a set term (e.g., up to 10 years).

Multi-year grant that rebates a portion of the municipal property tax increase resulting from approved building expansions or improvements in CIP areas.

Niagara Falls · Ontario · Canada

Ontario Creates IDM Fund – Concept Definition

Up to 50% of eligible costs, to a maximum of $50,000 for concept definition work.

Funding to support early-stage activities that move an interactive digital media product toward production, including prototypes, design, and business planning.

Ontario · Canada

Sustainable Tourism and Cultural Industries Fund (Provincial)

Funding toward sustainable operations, energy efficiency, and marketing.

Provincial fund supporting sustainable practices in tourism and cultural sectors including entertainment venues, digital upgrades, and sustainability initiatives.

Canada

Canada Media Fund – Innovation Program

Funding toward eligible development, production, or distribution activities.

Fund supporting innovative projects in the screen-based sector, including format innovation, distribution, and audience development; rolling intake for certain streams.

Canada

Edward R. Roybal Coordinating Center (R24 - Clinical Trial Not Allowed)

This FOA invites applications from qualified institutions to create a Roybal Center Coordinating Center (CC), serving the needs of the Roybal Centers for Translational Research on Aging program as well as the Roybal Centers for Translational Research on Dementia Care Provider Support program. The Roybal Coordinating Center will serve as a hub for the Roybal Center grant program. Roybal Center programs conduct translational in the behavioral and social sciences of aging, structured in accordance with the NIH Stage Model. Roybal Center program resources are intended for pilot and preliminary translational, multi-directional research at Stages 0 through IV of the behavioral intervention development pipeline with the goal of creating principle-driven interventions that improve the lives of mid-life and older people and the capacity of institutions to adapt to societal aging. The Roybal Coordinating Center will facilitate and coordinate trans-Roybal activities. The Center will work closely with the NIA Program Officer and, in coordination with all Roybal sites, will be responsive to requests generated by key Roybal site personnel, NIA, NIH, the scientific community, and the general public.

United States

Supporting Artistic Practice – Sector Innovation and Development

50% funding for project development, mentorship, networking, and sector innovation.

The Sector Innovation and Development component of Supporting Artistic Practice funds projects by Canadian and First Nations, Inuit and Métis arts professionals, cultural connectors, groups, and organizations that grow and improve the arts sector.

Canada

Perennial Crop Development Efficiency

75% funding for establishing and improving perennial crops, enhancing sustainability and efficiency.

Get up to $50,000 to cover up to 50% of eligible expenses to support your projects that focus on technologies designed to improve crop efficiency.

Prince Edward Island

NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional)

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage institutions to propose creative and innovative institutional research career development programs which will prepare clinically trained vision scientists for independent research careers. This NOFO is intended to expand and strengthen the community of clinician investigators engaged in vision research. . This Notice of Funding Opportunity (NOFO) allows the appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator as part of their research and career development program. For this career development program scholars are limited to clinical trials that are minimal risk. . The existing clinical trial must be a NIH-defined clinical trial that fulfills the NIH requirement for minimal risk trial. A minimal risk trial is one in which the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.. For the purposes of this announcement, institutions are highly encouraged to recruit prospective PIs/PDs, mentors, and scholars from underrepresented racial and ethnic groups as well as individuals with disabilities as described in the NOT-OD-22-019 in all of its programs.

United States

Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement is to provide tailored support for early stage investigators (ESIs) to initiate basic or translational research with nonhuman primates (NHPs). These awards will allow ESIs additional funds, time to generate preliminary data, and the opportunity to establish all skills needed to set up and run an NHP laboratory independently. It is expected that these awards will thereby improve an ESIs ability to secure larger research awards (e.g., R01) and will facilitate their transition to independent tenure-track positions.

United States

Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)

This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.

United States

Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)

This funding opportunity announcement (FOA) is designed to support highly integrated research teams of three to six PD/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields.Applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies or infrastructure development are not appropriate for this FOA.This FOA is being reissued to allow submission of applications that include NIH defined clinical trials. NIGMS will not accept clinical trials that are designed to test safety and efficacy of interventions (Phase I, Phase II, Phase III) for the purpose of future clinical treatment and/or regulatory approval in response to this FOA.

United States

Biomedical Technology Optimization and Dissemination Center (BTOD)(RM1-Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages applications for NIGMS Biomedical Technology Optimization and Dissemination (BTOD) Centers to support late-stage technology optimization and sustainable dissemination of the technology to the wider biomedical research community. A BTOD Center should be at the leading edge of its field with respect to both technology development and engagement with relevant research communities.. BTOD projects should address biomedical research areas within the NIGMS mission. This FOA is an update of the funding opportunity for the Biomedical Technology Development and Dissemination (BTDD) Centers (PAR-20-104). Potential applicants are strongly encouraged to consult with NIGMS staff about adherence of their proposed research strategy to the goals and mission of the Institute, whether it addresses one or more high priority research areas, and its responsiveness to this FOA.

United States

Industry Growth Program

Provides advisory services and grants to SMEs undertaking innovative commercialization and growth projects within the National Reconstruction Fund priority areas.

Australia

Genomic Community Resources (U24 Clinical Trial Not Allowed)

The purpose of this initiative is to facilitate genomic research and to disseminate its products to the broader biomedical research community. NHGRI supports both new and existing genomic resources of demonstrated broad value to the research community. Awards under this FOA will support the development and distribution of genomic resources that will be valuable for both basic and clinical genomics research. Such resources include, but are not limited to, those that support: . Genomic informatics toolsets, such as biomedical ontologies and analysis toolsets. . Comprehensive identification and collections of genomic features, such as functional genomic elements and genetic assay results. . Genomic community building efforts, such as standards development. . Sample repositories for genomic studies, such as cell line repositories for high-value samples.

United States

Lewis-Houghton Civics and Democracy Initiative

In the joint explanatory statement for the Legislative Branch Appropriations Act, 2023, Congress established the Lewis-Houghton Civics and Democracy Initiative and appropriated funds to the Library of Congress ‚Äúto develop and administer a pilot educational program as a part of the Initiative, which funds eligible organizations within the United States and its territories to develop digitally-enabled comprehensive, assessable teaching project-based creative arts driven curricula programs focused on using the digitized primary sources of the Library of Congress related to history, civics and democracy.‚Äů¬†. . . . . . . . The purpose of this notice is to identify awardee organizations that will design and implement digitally-enabled educational products in which the Library‚Äôs music or creative arts-focused primary sources and other online materials are central to teaching and learning.¬†. . . . . Awards made under Lewis-Houghton Civics and Democracy Initiative must include rights-free materials from the Library‚Äôs vast collections of music and creative arts-related resources to develop curriculum, teaching materials, and tools for history, civic and democracy instruction targeted toward high school students. . . . . . ¬†. . . . . Funded projects will support the . . Library‚Äôs mission . . to use its collections to connect with all Americans, including those representing diverse communities, beliefs and endeavors to engage, inspire and inform Congress and the American people with a universal and enduring source of knowledge and creativity.¬†. . . . . . . . See attached Notice of Funding Opportunity (NOFO)* for additional information. . . . . . *Please note the Notice has been amended as of May 25, 2023. The amended notice is available for download from the Related Documents section of this opportunity posting.

United States

Limited Competition: Alzheimers Disease Sequencing Project Follow-Up Study 2.0 (ADSP FUS 2.0): The Diverse Population Initiative (U01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, data calling, data sharing, data harmonization, and analysis that will support the generation of data from multi-ethnic cohorts for the Alzheimer's Disease Sequencing Project Follow-Up Study 2.0: The Diverse Population Initiative.

United States

Limited Competition: Human Pangenome Coordinating Center (U41) Clinical Trial Not Allowed

The National Human Genome Research Institute (NHGRI) will renew the Human Genome Reference Program (HGRP). This FOA will establish the Human Pangenome Coordinating Center (HPCC), the central component of the HGRP. The HPCC will serve as the logistic and scientific coordinating center for the HGRP and will create, improve, release, and maintain new pangenome reference versions. The overall goal of the HGRP during the renewal is to produce a human pangenome reference that optimizes both the population genetic diversity represented, along with the utility for, and adoption by, the genomics research community. This is a limited competition RFA. Only recipient organizations funded under RFA-HG-19-004 are eligible to apply.

United States

Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional)

The National Center for Advancing Translational Sciences (NCATS) will award Institutional Research Career Development (K12) programs through the Clinical and Translational Science Awards (CTSA).

United States

Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)

The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. . Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within.

United States

Livestock Strategy Program – Pollination Expansion

75% funding for livestock genetics, feed efficiency, and climate resilience projects.

Gain access to financial assistance to support the sustainable increase of local honeybee colonies that are available for pollination and the advancement of the beekeeping sector through strategic industry initiatives including investment in infrastructure.

Prince Edward Island

Junior Mining Assistance Program

The New Brunswick Junior Mining Assistance Program offers 50% funding for exploration, equipment, and travel.

Get up to $50,000 in financial support to cover 50% of eligible costs for mineral exploration projects.

New Brunswick

Doctoral Research Award: Vanier Canada Graduate Scholarships (2023-2024)

50% funding for health research, knowledge translation, and commercialization projects.

The Vanier Canada Graduate Scholarship (Vanier CGS) was created to attract and retain world-class doctoral students and to establish Canada as a global centre of excellence in research and higher learning. It is available to both Canadian and international PhD students studying at Canadian universities.

Canada

Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)

This initiative will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high risk approaches with potential for significant impact. Projects should entail a high degree of risk or novelty, which will be offset by a correspondingly high potential impact. However, the possible impact is likely to be far off. Application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. The goal of this FOA is to support proof of concept studies for feasibility and exploratory technology development. Feasibility must not have already been established in the literature or with preliminary data. Published data can be used to establish the current state of the art but cannot forecast or predict project outcomes. Preliminary data for any purpose might appear to forecast the likelihood of success. Therefore, no unpublished data is allowed. While unpublished data are not permitted, references and data from widely available preprints that have a Digital Object Identifier (DOI) are acceptable.

United States

Innovate BC Go-To-Market Microgrant

Provides non-repayable funding between $10,000 and $50,000 to support B.C. companies in addressing key early-stage go-to-market activities, enabling startups to build a repeatable sales process and generate consistent revenue.

British Columbia · Canada

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

United States

Investissement Québec – Productivité Innovation Initiative

Offers loans starting at $50,000 to help Quebec companies enhance their competitiveness and accelerate growth through innovation projects, including automation, digitization, and the use of artificial intelligence.

Quebec · Canada

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.

United States

Diagnostic Centers of Excellence (X01 Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement (FOA) is to provide investigators with access to resources provided by the Data Management Coordinating Center for Diagnostic Centers of Excellence (RFA-NS-22-051), as part of the next phase of the Undiagnosed Diseases Network. Resources include infrastructure, data management, and clinical research support for a new Network of clinical sites that provide diagnostic services for patients with undiagnosed diseases.

United States

Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of, pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research.

United States

Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.

United States

BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)

Reissue of RFA-NS-18-019: Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative. The invention, proof-of-concept investigation, and optimization of new technologies through iterative feedback from end users are key components of the BRAIN Initiative. This FOA seeks applications to optimize existing or emerging technologies through iterative testing with end users. The technologies and approaches should have potential to address major challenges associated with recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). These technologies and approaches should have previously demonstrated their transformative potential through initial proof-of-concept testing and are now ready for accelerated refinement. In conjunction, the manufacturing techniques should be scalable towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience research.Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.

United States

BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)

Reissue of RFA-NS-18-020: Understanding the dynamic activity of brain circuits is central to the NIH BRAIN Initiative. This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). This FOA seeks exceptionally creative approaches to address major challenges associated with recording and modulating CNS activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain. It is expected that the proposed research may be high-risk, but if successful, could profoundly change the course of neuroscience research. Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, magnetic, acoustic and/or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.

United States

Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Research Training Grant for the Clinical and Translational Science Awards (CTSA) Program (T32 Clinical Trial Not Allowed)

The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to enhance postdoctoral research training of individuals with health professional degrees and help ensure a heterogenous pool of clinical and translational scientists trainees are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications that improve health.

United States

Limited Competition: Lasker Clinical Research Scholars Transition Award (R00 Clinical Trial Optional)

The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

United States

Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. Additionally, D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.

United States

NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)

The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage.. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (FOA #).

United States

NIDA Program Project Grant Applications (P01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) announces the availability of support for collaborative research by multi-disciplinary teams which is of high priority to NIDA and leads to synergistic outcomes based on the synthesis of multiple research approaches. The NIDA Program Projects funding opportunity will support research in which the funding of three or more highly meritorious projects as a group enriches both the component projects and the overall program to offer significant scientific advantages over supporting the same projects as individual research grants (i.e., synergy). For the duration of the award, each Program must consist of a minimum of three research projects focused on issues critical to advance the mission and goals of NIDA.

United States

NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.

United States

Notice of Intent to Publish a Funding Opportunity Announcement for NIH Brain Development Cohorts Biospecimen Access (X01 Clinical Trial Not Allowed)

The National Institute on Drug Abuse intends to promote a new resource access program by publishing a Funding Opportunity Announcement (FOA) to seek applicationsÔř?f?or the following: NIH Brain Development Cohorts (NBDC) Biospecimen Access Program (X01- Clinical Trial Not Allowed). This FOA will allow investigators to apply for access to biological samples from the Adolescent Brain Cognitive DevelopmentSMÔř?(ABCD) Study. By making these specimens available to the greater scientific community, this resource award seeks to maximize the scientific potential of the biospecimens collected in the ABCD StudyÔř? and expand the scope of ABCDÔř?s open science model, allowing scientists from around the world to utilize these specimens and enrich the child and adolescent health data being obtained from the ABCD Study.Ôř?Ôř?. No funds will be provided through this opportunity. Applicants will be responsible for costs associated with conducting the research and sample shipment. Applicants will need to submit proof of funding for costs of analyses and sample shipment at the time of application.Ôř?Ôř?. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.Ôř?. The FOA is expected to be published in Spring 2023 with an expected application due date in SummerÔř?2023.. This FOA will utilize the X01 activity code. Details of the planned FOA are provided below.

United States

NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)

The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. . This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (FOA #).

United States

NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

United States

Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)

The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects.. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.

United States

Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P50 specialized centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

United States

Development of Animal Models and Related Biological Materials for Down Syndrome Research (R24 Clinical Trials Not-Allowed)

The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project encourages grant applications aimed at developing, characterizing, or improving animal models and related biological materials for Down syndrome (DS) related research and improving access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. With this funding opportunity announcement, the INCLUDE Project encourages, but is not limited to, projects focusing on development of various animal models, genetic resources, atlases at a single cell or subcellular level, advanced informatics technologies including artificial intelligence (AI) or machine learning (ML), and integration of multiple animal models and technology platforms for enhancing rigor and reproducibility of preclinical DS research.

United States

Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

United States

Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

This FOA solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities.

United States